Clinical Trial Update: Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Orelabrutinib with or without a CD20 monoclonal antibody in previously untreated marginal zone lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• CD20 monoclonal antibody
• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Marginal Zone Lymphoma(MZL) | Phase 4 | Status: RECRUITING